Journal of Antimicrobial Chemotherapy (2000) 45, 605-609
© 2000 The British Society for Antimicrobial Chemotherapy
High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998
a Servicio de Microbiología, Hospital de Móstoles, 28935 Móstoles, Madrid; b Area de Bioquímica y Biología Molecular, Universidad de la Rioja, Logroño, Spain
Using the standard agar dilution method we studied the prevalence of susceptibility to 14-, 15- and 16-membered ring macrolides and clindamycin in Streptococcus pyogenes isolated in 1998 from 21 laboratories in Spain. The number of strains admitted to the study was proportional to the numbers of inhabitants in each geographical area. We also determined the susceptibility phenotypes and the genetic basis for the antibiotic resistance. A total of 486 unduplicated isolates of S. pyogenes were used. Throat swab samples provided 359 (73.9%) isolates, and the remaining 127 isolates were from other sources. One hundred and fourteen (23.5%) isolates were resistant to erythromycin, a 14-membered ring macrolide, and azithromycin, a 15-membered macrolide, whereas only 1% of isolates were resistant to miocamycin, a 16-membered macrolide and 0.8% were resistant to clindamycin. Of the 114 erythromycin-resistant strains, 109 (95.6%) were susceptible to clindamycin and miocamycin. Since induction with erythromycin did not modify susceptibility to the latter antibiotics, these 109 strains were considered to have the M phenotype. Twenty strains with the M phenotype, one per laboratory, were assayed by PCR and showed the presence of the mef gene, which is responsible for antibiotic resistance by an efflux system. Among comparable studies covering entire countries, ours demonstrates one of the highest rates of S. pyogenes erythromycin resistance and clindamycin and miocamycin susceptibility in the world. Strains with the M phenotype account for the great majority of these isolates.
* Corresponding author. Tel: +34-91-6648695; Fax: +34-91-6471917.
See Acknowledgements.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. V. Hawkyard and R. J. Koerner The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks J. Antimicrob. Chemother., March 1, 2007; 59(3): 347 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tamayo, E. Perez-Trallero, J. L. Gomez-Garces, J. I. Alos, and on behalf of the Spanish Group for the Study of In Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004 J. Antimicrob. Chemother., October 1, 2005; 56(4): 780 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Haller, K. Fluegge, S. J. Arri, B. Adams, and R. Berner Association between Resistance to Erythromycin and the Presence of the Fibronectin Binding Protein F1 Gene, prtF1, in Streptococcus pyogenes Isolates from German Pediatric Patients Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2990 - 2993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. W. Klaassen and J. W. Mouton Molecular Detection of the Macrolide Efflux Gene: To Discriminate or Not To Discriminate between mef(A) and mef(E) Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1271 - 1278. [Full Text] [PDF]
|
|
|
|
|
|
Z. C. Acikgoz, E. Almayanlar, S. Gamberzade, and S. Gocer Macrolide Resistance Determinants of Invasive and Noninvasive Group B Streptococci in a Turkish Hospital Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1410 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Green, J. M. Martin, K. A. Barbadora, B. Beall, and E. R. Wald Reemergence of Macrolide Resistance in Pharyngeal Isolates of Group A Streptococci in Southwestern Pennsylvania Antimicrob. Agents Chemother., February 1, 2004; 48(2): 473 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Alos, B. Aracil, J. Oteo, J. L. Gomez-Garces, and the Spanish Group for the Study of Infection in th Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain J. Antimicrob. Chemother., February 1, 2003; 51(2): 333 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sauermann, R. Gattringer, W. Graninger, A. Buxbaum, and A. Georgopoulos Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 antibiotics J. Antimicrob. Chemother., January 1, 2003; 51(1): 53 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Malbruny, K. Nagai, M. Coquemont, B. Bozdogan, A. T. Andrasevic, H. Hupkova, R. Leclercq, and P. C. Appelbaum Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations J. Antimicrob. Chemother., June 1, 2002; 49(6): 935 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nagai, P. C. Appelbaum, T. A. Davies, L. M. Kelly, D. B. Hoellman, A. T. Andrasevic, L. Drukalska, W. Hryniewicz, M. R. Jacobs, J. Kolman, et al. Susceptibility to Telithromycin in 1,011 Streptococcus pyogenes Isolates from 10 Central and Eastern European Countries Antimicrob. Agents Chemother., February 1, 2002; 46(2): 546 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nagai, T. A. Davies, L. M. Ednie, A. Bryskier, E. Palavecino, M. R. Jacobs, and P. C. Appelbaum Activities of a New Fluoroketolide, HMR 3787, and Its (Des)-Fluor Derivative RU 64399 Compared to Those of Telithromycin, Erythromycin A, Azithromycin, Clarithromycin, and Clindamycin against Macrolide-Susceptible or -Resistant Streptococcus pneumoniae and S. pyogenes Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3242 - 3245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Aracil, M. Minambres, J. Oteo, C. Torres, J. L. Gomez-Garces, and J. I. Alos High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria J. Antimicrob. Chemother., October 1, 2001; 48(4): 592 - 594. [Full Text] [PDF]
|
|